Drug intelligence / Profile preview

NTT-006

Development stage: Preclinical
Lead developer: NTT Biopharma
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

**NTT-006** is an NTT Biopharma discovery-stage nanoparticle chemotherapy product that co-formulates **gemcitabine** and **cisplatin** in mesoporous silica nanoparticles. Gemcitabine disrupts DNA synthesis after intracellular activation to nucleotide metabolites, while cisplatin induces cytotoxic DNA crosslinks. The formulation is being developed for pancreatic cancer, liver cancer, and bile duct cancer.

Other names: gemcitabine + cisplatin formulated in mesoporous silica nanoparticles

Targets

DNA

Beyond the preview

Go deeper on NTT-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTT-006.

Explore the full profile